Supplementary Table 2. Adverse events and serious adverse events in the study population

Variable	Early combination (n=22)	Initial monotherapy (n=17)	P value
Adverse events			
Any primary system organ class	16 (72.7)	17 (100.0)	0.0192
Blood and lymphatic system disorders	2 (9.1)	3 (17.6)	0.4280
Eye disorders	4 (18.2)	4 (23.5)	0.6817
Gastrointestinal disorders	8 (36.4)	6 (35.3)	0.9450
Hepatobiliary disorders	2 (9.1)	2 (11.8)	0.7849
Infections and infestations	9 (40.9)	6 (35.3)	0.7208
Injury, poisoning and procedural complications	2 (9.1)	3 (17.6)	0.4280
Investigations	1 (4.5)	3 (17.6)	0.1811
Metabolism and nutrition disorders	3 (13.6)	4 (23.5)	0.4247
Musculoskeletal and connective tissue disorders	7 (31.8)	8 (47.1)	0.3320
Neoplasms benign, malignant and unspecified (including cysts and polyps)	1 (4.5)	2 (11.8)	0.4015
Nervous system disorders	4 (18.2)	3 (17.6)	0.9656
Renal and urinary disorders	2 (9.1)	2 (11.8)	0.7849
Reproductive system and breast disorders	0	3 (17.6)	0.0403
Skin and subcutaneous tissue disorders	1 (4.5)	3 (17.6)	0.1811
Serious adverse events			
Any primary system organ class	4 (18.2)	2 (11.8)	0.5818
Cardiac disorders (angina pectoris)	1 (4.5)	0	0.3732
Hepatobiliary disorders (cholecystitis acute)	1 (4.5)	0	0.3732
Musculoskeletal and connective tissue disorders (spinal osteoarthritis)	1 (4.5)	1 (5.9)	0.8511
Neoplasms benign, malignant and unspecified (hemangioma)	0	1 (5.9)	0.2491
Nervous system disorders (cerebral infarction)	1 (4.5)	0	0.3732

Values are presented as number (%). Patients with multiple adverse events under one treatment approach were counted only once in the adverse event category for that treatment approach.